The Study of Warfarin Maintenance Dose in Chinese Patients
NCT ID: NCT01855737
Last Updated: 2013-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2013-06-30
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
2. Drug: Warfarin
3. Design: To value the accuracy of warfarin Pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the Chinese patients.
4. Hypothesis:Pharmacogenomic algorithm guided dose can help to predict warfarin dose in Chinese patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients
NCT01610141
The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.
NCT02710747
Genotype-guided Warfarin Individualized Treatment
NCT02211326
A Prospective Cohort Study on Warfarin Personalized Medication
NCT06428110
Genotype-guided Versus Standard for Warfarin Dosing
NCT03479684
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Record the demographic information: gender, age, height, and weight.
* Record drug combination, complications, and international normalized ratio (INR), liver function and kidney function or other biochemical test results.
* Put genotypes, demographic information and other clinical information into the algorithm to calculate warfarin dose for the patients, and compared with the actual dose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Warfarin Using Group
Warfarin
Prescribe warfarin to the patients who are needed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Warfarin
Prescribe warfarin to the patients who are needed.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18y
* target INR 1.5\~3.0
* Patients signed informed consent
Exclusion Criteria
* Severe liver and kidney disfunction, serious infections, severe heart failure (NYHA heart function classification Ⅲ magnitude), severe pulmonary hypertension, abnormal thyroid function, respiratory failure, anemia, malignant tumor, blood disease
* patients with pregnancy or lactation;
* with cognitive impairment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Liu
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yishi Li, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Hong Liu, MS
Role: PRINCIPAL_INVESTIGATOR
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-GZH1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.